Immutep Ltd Sponsored ADR Stock
Immutep Ltd Sponsored ADR Stock price
Key metrics
| Market capitalization | $276.56m |
| Enterprise Value | $178.99m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.59 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-36.10m |
| Free Cash Flow (TTM) Free Cash Flow | $-29.76m |
| EPS (TTM) EPS | $-0.22 |
Is Immutep Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
Immutep Ltd Sponsored ADR Stock Analysis
Analyst Opinions
5 Analysts have issued a Immutep Ltd Sponsored ADR forecast:
Analyst Opinions
5 Analysts have issued a Immutep Ltd Sponsored ADR forecast:
Financial data from Immutep Ltd Sponsored ADR
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -1.52 -1.52 |
20%
20%
|
|
| EBITDA | -35 -35 |
16%
16%
|
EBIT (Operating Income) EBIT | -36 -36 |
16%
16%
|
| Net Profit | -29 -29 |
8%
8%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Immutep Ltd Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immutep Ltd Sponsored ADR Stock News
Company Profile
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
| Head office | Australia |
| CEO | Marc Voigt |
| Founded | 1987 |
| Website | www.immutep.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
